prevents NRF2 nuclear translocation to drive hypoperfusion-related cognitive deficits by targeting .

-based therapeutics represent a promising approach for treating multiple diseases, yet the key regulatory in chronic cerebral hypoperfusion (CCH)-related cognitive impairment remains unclear. Here, we identify as consistently upregulated in both male and female mild cognitive impairment (MCI) and late-stage of Alzheimer's disease (AD) patients, as well as in the basal forebrain of both male and female postmortem AD specimens and male CCH rats. Knockdown of in the basal forebrain alleviated CCH-induced cognitive deficits. Mechanistically, directly targeted Karyopherin alpha 5 (KPNA5), a nuclear transport protein that facilitates nuclear factor erythroid 2-related factor 2 (NRF2) nuclear translocation. suppressed via two binding sites in its 3'UTR, impairing NRF2-mediated antioxidant responses and promoting oxidative stress, and KPNA5 bound to three nuclear localization sequences of NRF2 through protein interaction. Restoration of the -KPNA5-NRF2 axis in the basal forebrain alleviated oxidative stress damage in male CCH rats, while no such effect was observed in the hippocampus. These findings reveal a potential role of the -KPNA5-NRF2 axis in CCH-related cognitive decline. Impairment of basal forebrain is recognized as an early event in the pathogenesis of Alzheimer's disease (AD) patients. () have emerged as promising therapeutic candidates for diseases involving complex pathological processes. In this study, we reveal a critical role for in AD progression and uncover a novel mechanism underlying chronic cerebral hypoperfusion (CCH)-induced cognitive decline in the basal forebrain of rats. We demonstrate that negatively regulates KPNA5 expression in the basal forebrain, thereby inhibiting the nuclear translocation of NRF2 and promoting oxidative stress-induced neuronal damage. Our findings identify as a potential therapeutic target for CCH-associated cognitive impairment and, notably, provide the first evidence implicating KPNA5 in the pathophysiology of neurodegenerative diseases.